In part two of our special focus on CREST-2, William Gray (Main Line Health, Philadelphia, USA) is once again joined in the CX Studio by Sonya Noor (Buffalo Endovascular and Vascular Surgical Associates, Buffalo, USA) and Richard Bulbulia (University of Oxford, Oxford, UK) as they dig deeper into what the results mean for medical therapy, whether there is a need for another trial, where it leaves transcarotid artery revascularisation (TCAR), and how the different specialties can better work together.
Watch the first instalment—Unpacking CREST-2, part one: “Which patient should be treated with which therapy?”—here.
